Xenon Pharmaceuticals to Showcase Innovations in Virtual Conference
Xenon Pharmaceuticals to Showcase Innovations in Virtual Conference
VANCOUVER, British Columbia and BOSTON — Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a leader in neuroscience-focused biopharmaceuticals, is excited to announce its involvement in the BofA Securities 2024 CNS Therapeutics Virtual Conference scheduled for October 7, 2024.
Details of the Presentation
Fireside Chat Presentation Schedule
The company will be participating through a live fireside chat aimed at sharing insights into their innovative approaches to tackling neurological and psychiatric disorders. Here are some important details:
- Date: Monday, October 7, 2024
- Time: 11:40 am Eastern Time
Webcast Availability
Interested individuals can access the live webcast of the presentation in the “Investors” section of Xenon’s website. The presentation will also be available for replay, ensuring that everyone has the opportunity to learn more about their remarkable advancements.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals is dedicated to discovering and developing innovative therapeutics aimed at improving the lives of patients facing neurological and psychiatric challenges. Their robust pipeline includes cutting-edge treatments that address significant unmet medical needs, particularly in epilepsy and depression.
Among these is Azetukalner, which stands out as a leading Kv7 channel opener that has demonstrated clinical promise in various applications. This product is a testament to Xenon's commitment to delivering novel therapies with enduring impact.
Company Mission and Vision
'Xenon' is not just a name but a symbol of hope for many. The company’s mission centers on transforming the landscape of treatment for complex conditions that affect mental health and overall well-being. Through rigorous research and development, Xenon strives to provide new solutions that can truly change lives.
Contact Information
For further inquiries, please reach out:
For Investors
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
Frequently Asked Questions
What is the significance of this virtual conference for Xenon Pharmaceuticals?
This event allows Xenon to present its latest findings and product developments to an audience of investors and industry professionals, enhancing its visibility.
Who can access the live webcast of the fireside chat?
The webcast is open to anyone interested in learning about Xenon's initiatives and will also be available for replay after the event.
What are the main therapeutic areas Xenon focuses on?
Xenon concentrates on neurological and psychiatric disorders, particularly in under-treated conditions like epilepsy and depression.
Where can I find more information about Xenon's products?
For more details, visiting the official website of Xenon Pharmaceuticals is recommended, as it provides comprehensive information on their product pipeline and research.
How is Azetukalner positioned in Xenon's treatment arsenal?
Azetukalner is highlighted as a leading candidate in Xenon's portfolio, being developed specifically for various indications which are currently in late-stage clinical development.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Unlocking the Power of AI: Highlights from Enterprise Connect
- Toyota's US Electric Vehicle Production Postponed to 2026
- Navigating All-Time Highs: S&P 500 Investment Insights
- Understanding Dockworker Salaries and the Impact of Strikes
- Humana Inc. Faces Investigation, What Investors Should Know
- Exploring the Impact of Velocity Commercial Capital's Ratings
- Investors Alert: AMMO Incorporated Faces Securities Class Action
- Empowering Unity: Highlights from the Texas Women's Conference
- Empowering Financial Literacy in Alabama with Operation HOPE
- New Addiction Treatment Facility Launches in Oklahoma City
Recent Articles
- Olema Oncology Expands Employee Incentives with Stock Options
- Olema Oncology Announces Inducement Grants for Employees
- Top Cannabis Stock Moves: Gainers and Losers Insights
- Spero Therapeutics Shares Breakthrough Phase 1 Data on SPR720
- Bullish Trends Highlight Unusual Options Activity for MRNA
- Comstock Inc. Unveils Insights from 3Q24 Stakeholder Analysis
- Glacier Bancorp, Inc. Prepares for Upcoming Earnings Call
- Understanding Accenture's Options Activity and Market Trends
- Golden Ocean Group Announces Extension of Share Buy-Back Program
- A Deep Dive into Zscaler's Recent Option Trading Insights
- Greif Celebrates Recognition as a Leading Workplace for 2024
- Biden's Strategic Oil Trade: A Bold Move for Energy Security
- Insights into Cellectis Voting Rights and Shareholder Information
- Invitation Homes Sharing Q3 2024 Results & Conference Details
- Plains All American Pipeline's Q3 2024 Distributions Explained
- Primaris REIT Announces Major Offering for Strategic Growth
- Ryan Specialty to Reveal Q3 Financial Highlights Soon
- Heritage Commerce Corp Welcomes Thomas A. Sa as New COO
- Top 20 Most-Searched Tickers of September: Insights Unveiled
- CF Industries Announces Dividend and Upcoming Earnings Call
- Ameresco Unveils Largest Landfill Gas to Renewable Natural Gas Facility
- Ecolab's Long-Term Investment Return: A 20-Year Analysis
- Riot Platforms: A Decade of Growth and Investment Potential
- XPO Announces Q3 2024 Earnings Call Details and Insights
- Maryland American Water's Acquisition Triumph Promises Reliability
- Know Labs Faces Compliance Challenges with NYSE American
- Ollie's Bargain Outlet Expands with Strategic Store Acquisitions
- Levi Strauss & Co Reports Q3 Earnings: A Closer Look at Results
- Exploring Bourbon Investment: CaskX Shines at Festival Event
- Aquaron Acquisition Corp. Secures Trust Account Funding for Deal
- Centerspace Acquires The Lydian and Updates Financials
- Penumbra, Inc. Plans Q3 2024 Earnings Call on October 30
- Radiant Logistics' Strategic Move: Acquisition of Focus Logistics
- F.N.B. Corporation Supports Hurricane Relief with $100,000 Donation
- Codexis Secures $31 Million to Propel Growth into 2027
- First Citizens BancShares Sets Date for Earnings Review Call
- Fidelity National Financial Expands Presence with Strategic Acquisition
- Polu Kai Services Secures Major Contract for Military Support
- Tesla Price Target Elevated: What Investors Should Know
- BigCommerce Welcomes Travis Hess as Its New Chief Executive
- Globus Medical Enhances Trauma Product Line with Innovations
- Certara Strengthens Drug Development with Chemaxon Acquisition
- Corner Growth Acquisition Corp. 2's Strategic Shift in Accounting
- Humana Faces Challenges as BofA Downgrades Outlook
- iSpecimen Navigates Challenges After Regaining Nasdaq Compliance
- Levi Strauss Explores Strategic Options for Dockers Brand
- Positive Trends in Brazilian Stocks as Bovespa Closes Higher
- Mulvihill Canadian Bank ETF Announces Monthly Cash Distribution
- MidCap Financial Investment Corporation Announces Q3 Earnings Call Schedule
- Covenant Logistics Group Plans Q3 Earnings Call Announcement